Technical Analysis for CRY - CryoLife, Inc.

Grade Last Price % Change $ Change
grade F $16.75 2.76% 0.45
CRY closed up 2.76 percent on Wednesday, February 22, 2017, on 2.16 times normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical CRY trend table...

Date Alert Name Type % Chg
Feb 22 Lower Bollinger Band Walk Other 0.00%
Feb 21 180 Bearish Setup Bearish Swing Setup 2.76%
Feb 17 Volume Surge Other -2.90%
Feb 17 Jack-in-the-Box Bearish Bearish Swing Setup -2.90%
Feb 16 Fell Below 50 DMA Bearish 4.04%
Feb 16 200 DMA Support Bullish 4.04%
Feb 16 Volume Surge Other 4.04%
Feb 16 Wide Range Bar Range Expansion 4.04%
Feb 16 Expansion Breakdown Bearish Swing Setup 4.04%
Feb 16 180 Bearish Setup Bearish Swing Setup 4.04%

Older signals for CRY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLife’s proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Is CRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.15
52 Week Low 10.21
Average Volume 167,230
200-Day Moving Average 16.07
50-Day Moving Average 18.8
20-Day Moving Average 18.31
10-Day Moving Average 17.93
Average True Range 0.82
ADX 20.89
+DI 10.75
-DI: 33.04
Chandelier Exit (Long, 3 ATRs) 17.14
Chandelier Exit (Short, 3 ATRs) 17.66
Upper Bollinger Band 20.16
Lower Bollinger Band 16.46
Percent B (%b) 0.08
Bandwidth 0.202075